Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. (Q38082728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

3

Jos H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Bastiaan Nuijen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jan H M Schellens

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

1 reference

1 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

399-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420518%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40262-013-0040-2

24 February 2020

exact match

0 references

cites work

Oral cancer treatment: developments in chemotherapy and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Patient preferences for oral versus intravenous palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Patient adherence and persistence with oral anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Metastatic breast cancer: we do need primary cost data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

First-pass elimination. Basic concepts and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Predicting drug absorption: how nature made it a difficult problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Measurement of gastrointestinal pH profiles in normal ambulant human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetic optimisation of treatment with oral etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Can food affect the bioavailability of chlorambucil in patients with haematological malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Drug-like properties and the causes of poor solubility and poor permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Drug delivery strategies for poorly water-soluble drugs: the industrial perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Intestinal lymphatic transport for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

How important is intestinal cytochrome P450 3A metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Anticancer oral therapy: emerging related issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The drug efflux-metabolism alliance: biochemical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The effect of dose on the bioavailability of oral etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Probiotics in the gastrointestinal diseases of the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Liver function and phase I drug metabolism in the elderly: a paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effects of food on the relative bioavailability of lapatinib in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacogenetic pathway analysis of docetaxel elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Part 1: background, methodology, and clinical adoption of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmaceutical Applications of Solid Dispersion Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Review: physical chemistry of solid dispersions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The absolute bioavailability of oral vinorelbine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Etoposide phosphate, the water soluble prodrug of etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Microemulsions for oral administration and their therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Development of microemulsion of mitotane for improvement of oral bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Development of a supersaturable SEDDS (S‐SEDDS) formulation of paclitaxel with improved oral bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Triazine dendrimers as drug delivery systems: from synthesis to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

The effect of novel surfactants and Solutol HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Cyclodextrins and their pharmaceutical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

P-glycoprotein inhibition by membrane cholesterol modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Interaction of modified cyclodextrins with cytochrome P-450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Capecitabine for locally advanced and metastatic colorectal cancer: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effective oral chemotherapy for breast cancer: pillars of strength.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Health literacy and outcomes among patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Moving towards dose individualization of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Effect of grapefruit juice intake on etoposide bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Oral topotecan: bioavailablity and effect of food co-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Clinical pharmacokinetics of idarubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Randomly methylated β‐cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco‐2 cell monolayer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0040-2

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors

21 January 2018

1 reference

12 December 2020

Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease

1 reference

12 December 2020

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel

1 reference

12 December 2020

Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors

1 reference

12 December 2020

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate

1 reference

12 December 2020

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel

1 reference

12 December 2020

Anti-proliferation and anti-angiogenesis of curcumin-K30 solid dispersion

1 reference

12 December 2020

Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia

1 reference

12 December 2020

Aging biology and geriatric clinical pharmacology

1 reference

12 December 2020

Pharmacokinetics of navelbine after oral administration in cancer patients

1 reference

12 December 2020

Patient selection for oral chemotherapy.

1 reference

12 December 2020

Changes, functional disorders, and diseases in the gastrointestinal tract of elderly

1 reference

12 December 2020

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Relative bioavailability of two oral formulations of navelbine in cancer patients

1 reference

12 December 2020

Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes.

1 reference

12 December 2020

Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors

1 reference

12 December 2020

Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1.

1 reference

12 December 2020

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

1 reference

12 December 2020

A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil

1 reference

12 December 2020

Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies

1 reference

12 December 2020

1 reference

12 December 2020

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

1 reference

12 December 2020

Chemotherapy dosing in the setting of liver dysfunction.

1 reference

12 December 2020

Pharmacological attempts to improve the bioavailability of oral etoposide

1 reference

12 December 2020

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A

1 reference

12 December 2020

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001)

1 reference

12 December 2020

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

1 reference

12 December 2020

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats

1 reference

12 December 2020

Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient

1 reference

12 December 2020

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

1 reference

12 December 2020

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies

1 reference

12 December 2020

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites

1 reference

12 December 2020

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

1 reference

12 December 2020

Patient adherence to oral anticancer drugs: an emerging issue in modern oncology

1 reference

12 December 2020

Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues

1 reference

12 December 2020

A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel

1 reference

12 December 2020

Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration

1 reference

12 December 2020

Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats

1 reference

12 December 2020

Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles

1 reference

12 December 2020

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.

1 reference

12 December 2020

Changes in the intestinal absorption mechanism of icariin in the nanocavities of cyclodextrins

1 reference

12 December 2020

Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions

1 reference

12 December 2020

Stability of the i.v. and oral formulations of etoposide in solution

1 reference

12 December 2020

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin

1 reference

12 December 2020

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

1 reference

12 December 2020

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

12 December 2020

The developability classification system: application of biopharmaceutics concepts to formulation development

1 reference

12 December 2020

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

12 December 2020

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

1 reference

12 December 2020

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients

1 reference

12 December 2020

Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits

1 reference

12 December 2020

Pharmacokinetics of ftorafur after intravenous and oral administration

1 reference

12 December 2020

Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients

1 reference

12 December 2020

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir

1 reference

12 December 2020

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

1 reference

12 December 2020

Bioavailability of low-dose oral etoposide

1 reference

12 December 2020

Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs

1 reference

12 December 2020

Gastrointestinal pH profiles in patients with inflammatory bowel disease

1 reference

12 December 2020

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors

1 reference

12 December 2020